One of the most-read ophthalmic business stories from the first half of September was about a large fine for Novartis and Roche/Genentech in France.
Here are some other recent ophthalmic business articles that have run on Healio/OSN so far this month.
Novartis, Roche/Genentech face major fines from French regulatory authority
Novartis and Roche/Genentech are facing a combined 444 million euros in fines from the French Competition Authority for “abusive practices” intended to sustain sales of an expensive product. Read more.
VIDEO: Tarsus works to develop Demodex blepharitis treatment
Uncategorized